About the Author

Dr. Santiago is a lead research microbiologist at the Centers for Disease Control and Prevention in San Juan, Puerto Rico. His research is focused on the development of molecular diagnostic tests and genomic epidemiology of dengue virus and severe acute respiratory syndrome coronavirus 2.

References

1. Sharp TM, Quandelacy TM, Adams LE, Aponte JT, Lozier MJ, Ryff K, et al. Epidemiologic and spatiotemporal trends of Zika virus disease during the 2016 epidemic in Puerto Rico. PLoS Negl Trop Dis. 2020;14:e0008532. https://doi.org/10.1371/journal.pntd.0008532

2. Quick J, Grubaugh ND, Pullan ST, Claro IM, Smith AD, Gangavarapu K, et al. Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples. Nat Protoc. 2017;12:1261–76. https://doi.org/10.1038/nprot.2017.066

3. Grubaugh ND, Gangavarapu K, Quick J, Matteson NL, De Jesus JG, Main BJ, et al. An amplicon-based sequencing framework for accurately measuring intrahost virus diversity using PrimalSeq and iVar. Genome Biol. 2019;20:8. https://doi.org/10.1186/s13059-018-1618-7

4. Santiago GA, Vázquez J, Courtney S, Matías KY, Andersen LE, Colón C, et al. Performance of the Trioplex real-time RT-PCR assay for detection of Zika, dengue, and chikungunya viruses. Nat Commun. 2018;9:1391. https://doi.org/10.1038/s41467-018-03772-1

5. Metsky HC, Matranga CB, Wohl S, Schaffner SF, Freije CA, Winnicki SM, et al. Zika virus evolution and spread in the Americas. Nature. 2017;546:411–5. https://doi.org/10.1038/nature22402

6. Faria NR, Quick J, Claro IM, Thézé J, de Jesus JG, Giovanetti M, et al. Establishment and cryptic transmission of Zika virus in Brazil and the Americas. Nature. 2017;546:406–10. https://doi.org/10.1038/nature22401

7. Black A, Moncla LH, Laiton-Donato K, Potter B, Fardo L, Rico A, et al. Genomic epidemiology supports multiple introductions and cryptic transmission of Zika virus in Colombia. BMC Infect Dis. 2019;19:963. https://doi.org/10.1186/s12879-019-0372-1

8. Grubaugh ND, Saraf S, Gangavarapu K, Watts A, Tan AL, Oidtman RJ, et al.; GeoSentinel Surveillance Network. Travel surveillance and genomics uncover a hidden Zika outbreak during the waning epidemic. Cell. 2019;178:1057–1071.e11. https://doi.org/10.1016/j.cell.2019.07.018

9. Peters R, Stevenson M. Zika virus diagnosis: challenges and solutions. Clin Microbiol Infect. 2019;25:142–6. https://doi.org/10.1016/j.cmi.2018.12.002

Address for correspondence: Jorge L. Muñoz-Jordan, Centers for Disease Control and Prevention, 1324 Cañada St, San Juan, PR 00920, USA; email jmunoz@cdc.gov.

Fatal Systemic Capillary Leak Syndrome after SARS-CoV-2 Vaccination in Patient with Multiple Myeloma

Gwang-Jun Choi, Seon Ha Baek, Junmo Kim, Jung Ho Kim, Geun-Yong Kwon, Dong Keun Kim, Yeon Haw Jung, Sejoong Kim

Author affiliations: Daegu Metropolitan Government, Daegu, South Korea (G.-J. Choi); Hallym University Dongtan Sacred Heart Hospital, Hwaseong, South Korea (S.H. Baek); National Forensic Service Daegu Institute, Daegu (J. Kim); Yeungnam University College of Medicine, Daegu (J.H. Kim); Korea Disease Control and Prevention Agency, Cheongju, South Korea (G.-Y. Kwon, D.K. Kim, Y.H. Jung); Seoul National University Bundang Hospital, Seongnam, South Korea (S. Kim)

DOI: https://doi.org/10.3201/eid2711.211723

A young man with smoldering multiple myeloma died of hypotensive shock 2.5 days after severe acute respiratory syndrome coronavirus 2 vaccination. Clinical findings suggested systemic capillary leak syndrome (SCLS); the patient had experienced a previous suspected flare episode. History of SCLS may indicate higher risk for SCLS after receiving this vaccine.

Systemic capillary leak syndrome (SCLS) is an extremely rare disease of unknown incidence (1). Typical manifestations of SCLS include hypotension, edema, hemoconcentration, and hypoalbuminemia after nonspecific prodromal illnesses (1,2). Increased capillary vascular permeability is the commonly accepted pathophysiology (1,2). However, the exact pathogenesis remains unclear.

As part of the efforts to combat the ongoing pandemic of coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, the US Food and Drug Administration on February 27, 2021, gave emergency use authorization to the Ad26.COV2.S vaccine (Johnson & Johnson/Janssen, https://www.jnj.com). An SCLS case series reported 1 case of SCLS in a patient who received the Ad26.COV2.S vaccine (3). The European Medicines Agency reviewed 3 cases of SCLS in Ad26.COV2.S vaccine recipients and issued a report, published July 9, 2021, advising against administering the vaccine in persons with previous SCLS experiences (4). We describe a case of SCLS after Ad26.COV2.S vaccination in a patient with smoldering multiple myeloma.

A 38-year-old man reporting vomiting and dizziness sought treatment at an emergency department.
Smoldering multiple myeloma had been diagnosed 1.5 years before, but no laboratory abnormalities had been found in his most recent hospital visit 5 months earlier. He had received the Ad26.COV2.S vaccine 2 days before the emergency department visit and experienced fever, chills, and myalgia 12–24 hours postvaccination, then nausea, recurrent vomiting, and general weakness 24–48 hours postvaccination. At admission, he was afebrile, his heart rate was 130 beats/min, and his blood pressure was 100/90 mm Hg, with no noticeable edema. We administered isotonic saline and initiated diagnostic evaluations: laboratory tests, imaging, and COVID-19 reverse transcription PCR. Test results (Table) showed marked hemococoncentration and hypoalbuminemia. Chest and abdominal computed tomography results were unremarkable. Six hours after admission, the patient was hypotensive (blood pressure 60/40 mm Hg), had a heart rate of 132 beats/min, and reported dyspnea. We obtained blood cultures and treated the patient with broad-spectrum antimicrobials, intravenous fluids, and inotropes. Despite these measures, the patient’s hypotensive shock worsened, and he died 10 hours after admission.

Although at admission the patient showed neither peripheral edema nor severe hypoalbuminemia, we suspected SCLS for several reasons. First, we could not entirely rule out infection, but results of blood cultures and COVID-19 testing were negative. Second, autopsy results showed no evidence of acute infection or cardiovascular disease in the internal organs. We identified pulmonary edema, pleural effusion, and pericardial effusion. Although pulmonary edema is atypical in acute SCLS attacks (leak phase), prolonged cardiopulmonary resuscitation and fluid administration might have affected the autopsy findings. Histopathologic findings in both kidneys suggested autolysis or acute tubular necrosis, which helped exclude other possible etiologies of refractory hypotensive shock. Third, through medical chart review, we found that the patient in our study had been admitted 1.5 years earlier for fever, vomiting, myalgia, generalized edema, and hypotension (blood pressure 90/60 mm Hg). Laboratory results showed hemoconcentration (hematocrit 58.4%) and hypoalbuminemia (3.03 g/dL at nadir), but diagnosis was unclear, and the patient recovered spontaneously after fluid administration. We retrospectively assumed a flare episode of SCLS. Fourth, ~80% of patients with SCLS have monoclonal gammopathy of undetermined significance (MGUS) (2,5), and there have also been other reports of SCLS in patients with multiple myeloma (2). The patient who had the previous reported case of SCLS after Ad26.COV2.S vaccination had MGUS (3), and the patient in our study had multiple myeloma. Recently, an additional report described a patient with MGUS who experienced severe SCLS 2 days after receiving the ChAdOx1 nCOV-19 vaccine (Oxford/AstraZeneca; https://www.astrazeneca.com); that patient also had an unrecognized previous episode of presumed SCLS (6).

We believe a life-threatening flare developed after COVID-19 vaccination in the patient in our study who had a history suggestive of SCLS. Clinical findings were compatible with a previous report in which life-threatening disease occurred 1–2 days after vaccination (3,6); we could identify no SCLS triggers other than receiving the COVID-19 vaccine. Data from a review article

**Table.** Results of laboratory tests in patient with smoldering multiple myeloma who had SCLS develop after vaccination for severe acute respiratory syndrome coronavirus, South Korea*

| Clinical measures                      | Reference range | Test results after SCLS episodes |
|----------------------------------------|-----------------|---------------------------------|
|                                        |                 | 5 mo earlier | Postvaccination |
| Leukocytes, ×10⁹/mm³                    | 4–10            | 6.88        | 29.42           |
| Hemoglobin, g/dL                       | 13–17           | 14.7        | 22.7            |
| Hematocrit, %                          | 40–52           | 44.3        | 63.7            |
| Platelet, ×10⁹/mm³                     | 140–440         | 259         | 133             |
| Albumin, g/dL                          | 3.5–5.0         | 4.8         | 3.3             |
| Blood urea nitrogen, mg/dL             | 8–23            | 13.6        | 33              |
| Creatinine, mg/dL                      | 0.7–1.2         | 0.94        | 2.0             |
| Aspartate transaminase, IU/L           | 10–35           | 22          | 30              |
| Alanine transferase, IU/L              | 0–40            | 14          | 4               |
| Total bilirubin, mg/dL                 | 0.1–1.2         | 0.5         | 1.46            |
| Calcium, mg/dL                         | 8.6–10.6        | 10.0        | 8.9             |
| Erythrocyte sedimentation rate, mm/h   | 0–20            | Not done    | 13              |
| C-reactive protein, mg/dL              | 0–0.5           | Not done    | 2.371           |
| Procalcitonin, ng/ml                   | 0–5             | Not done    | 0.641           |
| Troponin I, ng/mL                      | 0–0.04          | Not done    | 0.017           |
| Creatine kinase myocardial band, ng/mL | 0.6–6.3         | Not done    | 3.5             |
| N terminal-pro B-type natriuretic peptide, pg/mL | 0–125 | 35.1 | 4,427 |
| Lactic acid, mmol/L                    | 0.5–1.6         | Not done    | 5.4             |
| Creatine phosphokinase, IU/L           | 1–171           | Not done    | 276             |

*Vaccine was Ad26.COV2.S (Johnson & Johnson/Janssen, https://www.jnj.com). SCLS, systemic capillary leak syndrome.
indicated that 44% of 134 patients had identifiable SCLS triggers; 88% of those were infections, usually respiratory, and 11% involved intense physical exertion or extended travel (7). There was also a case report of possible SCLS related to the influenza vaccine; although not clearly meeting all the criteria for SCLS, a peritoneal dialysis patient experienced recurrent episodes of hypotension, peripheral edema, and hypoalbuminemia after 2 consecutive seasons of influenza vaccination (8). Immunologic response to vaccination has been proposed as a possible mechanism (8), but further studies are needed to verify factors predisposing patients to SCLS after COVID-19 immunization.

In South Korea, 1,129,796 people had received the Ad26.COV2.S vaccine as of August 2, 2021 (9); we have found no other reports of possible SCLS in vaccine recipients in South Korea. Our report describes the clinical course and characteristics of SCLS after COVID-19 vaccination. SCLS is often difficult to diagnose and may be misdiagnosed as other diseases, such as culture-negative sepsis. Therefore, clinicians should be aware of possible SCLS, especially in at-risk populations, and medical histories should be examined before vaccine is administered.

Acknowledgments
The authors express our deepest condolences to the bereaved family of the patient.

About the Author
Dr. Choi is an epidemic intelligence officer in the Daegu Metropolitan Government in Daegu, South Korea. His current research interest is adverse events following immunization.

References
1. Siddall E, Khatri M, Radhakrishnan J. Capillary leak syndrome: etiologies, pathophysiology, and management. Kidney Int. 2017;92:37–46. https://doi.org/10.1016/j.kint.2016.11.029
2. Druey KM, Greipp PR. Narrative review: the systemic capillary leak syndrome. Ann Intern Med. 2010;153:90–8. https://doi.org/10.7326/0003-4819-153-2-201007200-00005
3. Matheny M, Maleque N, Channell N, Eisch AR, Auld SC, Banerji A, et al. Severe exacerbations of systemic capillary leak syndrome after COVID-19 vaccination: a case series. Ann Intern Med. 2021 June 15 [Epub ahead of print]. https://doi.org/10.7326/L12-0250
4. European Medicines Agency. EMA advises against use of COVID-19 vaccine Janssen in people with history of capillary leak syndrome [cited 2021 July 9]. https://www.ema.europa.eu/en/news/ema-advises-against-use-covid-19-vaccine-janssen-people-history-capillary-leak-syndrome
5. Baek SH, Shin N, Kim HJ, Han MY, Choi DJ, Bang SM, et al. A case of chronic renal failure associated with systemic capillary leak syndrome. Yeungnam Univ J Med. 2012;29:145–9. https://doi.org/10.12701/yujm.2012.29.2.145
6. Julie Robichaud, Catherine Côté, Fanny Côté. Systemic capillary leak syndrome after ChAdOx1 nCOV-19 (Oxford–AstraZeneca) vaccination. CMAJ. 2021 Aug 6 [Epub ahead of print]. https://doi.org/10.1503/cmaj.211212
7. Druey KM, Parikh SM. Idiopathic systemic capillary leak syndrome (Clarkson disease). J Allergy Clin Immunol. 2017;140:663–70. https://doi.org/10.1016/j.jaci.2016.10.042
8. Geerse DA, Meynen FM, Gelens MA, Koorman JP, Cornelis T. Systemic capillary leak syndrome after influenza vaccination in a peritoneal dialysis patient. Perit Dial Int. 2015;35:772–3. https://doi.org/10.3747/pdi.2014.00194
9. Korea Disease Control and Prevention Agency. Cumulative COVID-19 vaccine doses administered in Republic of Korea [cited 2021 August 2]. https://www.kdca.go.kr/board/board.es?mid=a21501010000&bid=0015&list_no=714208&cg_code=&act=view&nPge=7

Address for correspondence: Sejoong Kim, Department of Internal Medicine, Seoul National University Bundang Hospital, 82, Gumiro 173beon-gil, Bundang-gu, Seongnam, Gyeonggi-do, South Korea; email: sejoong@snubh.org